|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.49 - 0.57|
|52 Week Range||0.46 - 0.84|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.00|
VANCOUVER, Washington, April 11, 2018-- CytoDyn Inc., a biotechnology company developing new antibody therapies for combating human immunodeficiency virus infection, announces that an abstract with primary ...
VANCOUVER, Washington, March 29, 2018-- CytoDyn Inc. announces the formation of a Scientific Advisory Board to advise on the development of PRO 140 in certain immunologic disorders. PRO 140 is a humanized ...
Glancy Prongay & Murray LLP announces an investigation on behalf of CytoDyn Inc. investors concerning the Company and its directors’ and officers’ possible violations of state laws.
VANCOUVER, Washington, March 14, 2018-- CytoDyn Inc., a biotechnology company developing new antibody therapies for combating human immunodeficiency virus infection, announces that the Independent Data ...
NEW YORK, NY / ACCESSWIRE / February 2 2 , 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of CytoDyn Inc. (OTCQB: CYDY ) and Q Biomed Inc. (OTCQB: QBIO ...